Initiate a pivotal study for zanidatamab plus chemotherapy as first-line treatment for advanced HER2-positive GEA
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- December 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to initiate, with partner BeiGene, a pivotal study for zanidatamab plus chemotherapy +/- tislelizumab (anti-PD1), as first-line treatment for advanced HER2-positive GEA in mid-2021.”
What we found
Evidence strength A What the grades mean
The company announced the initiation of the pivotal HERIZON-GEA-01 trial in December 2021, which occurred after the mid-2021 deadline.
-
A Zymeworks Inc. 10-K filed 2022-02-24
“Also in December 2021, we announced that our partner, BeiGene, dosed the first patient in the HERIZON-GEA-01 trial, a global, randomized, Phase 3 clinical trial designed to evaluate the efficacy and safety of zanidatamab” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- pivotal study for zanidatamab plus chemotherapy
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: with partner BeiGene
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Zymeworks Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C403752-022117 · Corrections policy